EMD Serono Submits Application For Cladribine Tablets As A Potential Oral Short-Course Multiple Sclerosis Therapy In The United States

Links shared publicly online about this topic.

  • 1,709
    total visits

EMD Serono Submits Application For Cladribine Tablets As A Potential Oral Short-Course Multiple Sclerosis Therapy In The United States

medicalnewstoday.com —

EMD Serono, Inc. an affiliate of Merck KGaA, Darmstadt, Germany, announced the submission of a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for Cladribine Tablets, EMD S

View full resource at medicalnewstoday.com

Tags: Multiple Sclerosis, Drug, FDA, Merck & Co., Merck KGaA

  • Share

Most Recently Shared on October 1, 2009 at 1:48 pm By:

LisaEmrich Lisa Emrich

MedNewsToday: EMD Serono Submits Application For Cladribine Tablets As A Potential Oral Short-Cour.. http://bit.ly/ec7W6

3 years ago...

Reply

Retweet

Favorite

Also Shared By:

MNT Clinical Trials MNT Clinical Trials

Advertisement